Intellia to Present Phase 3 Lonvo-z HAE Trial Data at EAACI
Intellia Therapeutics announced that data from its global Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026. Lonvo-z, a CRISPR-based gene editing therapy, aims to be a one-time treatment for HAE by permanently lowering kallikrein. The company will also present a poster on the burdens faced by HAE patients outside the U.S.
Key Highlights
- Phase 3 HAELO clinical trial data for lonvo-z in HAE to be presented.
- Presentation at EAACI Annual Congress 2026, June 12-15, in Istanbul.
- Late-breaking oral presentation on Saturday, June 13, 2026.
- Lonvo-z is a CRISPR-based gene editing therapy for hereditary angioedema.
- Lonvo-z has received five notable regulatory designations.
- Hereditary angioedema affects an estimated one in 50,000 people.
Price Impact
More from NTLA
Intellia lonvo-z Phase 3 HAELO Trial Shows 87% HAE Attack Reduction
Intellia Therapeutics Q1 Net Loss $(96.2M), EPS $(0.81); Lonvo-z Phase 3 Positive
Intellia Therapeutics Reports Positive Lonvo-z Phase 3 Data, Initiates BLA; Q1 Net Loss $96.2M